Ligand invests in the clinical development and commercialization of high-value medicines. We manage one of the largest and most diverse portfolios of biopharmaceutical royalties in the industry, with more than 90 partnered commercial and development stage programs.

JUPITER, Fla., March 03, 2025 (GLOBE NEWSWIRE) - Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: Leerink Partners Global Healthcare Conference (Miami).

2025年2月27日 · Ligand management will host a conference call and webcast today beginning at 8:30 a.m. Eastern time to discuss this announcement and answer questions. “We achieved significant revenue growth in 2024 driven by strong momentum across our major commercial programs,” said Todd Davis, CEO of Ligand.

2025年2月28日 · At Ligand Pharmaceuticals Incorporated, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further ...

2024年12月10日 · At today’s event, Ligand’s senior management team will highlight: Ligand’s transformation over the past two years into a profitable, diversified, and infrastructure light organization that enables investors to participate in the innovation and promise of the biotech industry while avoiding concentrated binary risk

2025年2月13日 · Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2024 financial results before the opening of the U.S. financial markets on Thursday, February 27, 2025.

2025年2月25日 · Ligand’s Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand’s NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications.

2025年2月27日 · Ligand is a biopharmaceutical company that invests in the groundbreaking medicines of today and tomorrow. We fund the clinical development and commercialization of high-value programs that can improve and extend lives around the world.

2024年3月31日 · Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three months ended March 31, 2024, and provided an operating forecast and business updates.

Today, Ligand manages one of the largest and most diverse portfolios of biopharmaceutical royalties in the industry, with more than 90 partnered commercial and development-stage programs. The assets in our portfolio include treatments for cancer, kidney disease, diabetes, nonalcoholic steatohepatitis, and other rare conditions that threaten ...